Treatment of chronic hepatitis C infection with direct acting antivirals: effects on liver fibrosis and patient reported outcomes

Treatment of chronic hepatitis C infection with direct acting antivirals: effects on liver fibrosis and patient reported outcomes - DURACE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42320

Enrollment

100

Registered

2015-04-23

Start date

2015-01-28

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C infection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Chronic hepatitis C - Age > 18 years - METAVIR score F3-F4 (classified by liver biopsy or Fibroscan score >9,5 kPa) - Status after liver transplantation or on the waiting list for liver transplantation - Severe extra hepatic disease (HCV-related skin disease like prophyria cutanea tarda or leukocytoclastic vasculitis; or HCV related renal impairment secondary to cryoglobulinemia

Exclusion criteria

Exclusion criteria: - Patients who don't meet the criteria for DAA treatment - Patients who are not able to visit the outpatient clinic at regular basis

Design outcomes

Primary

Measure	Time frame
• Liver stiffness measurements • Parameters of portal hypertension • Serum fibrosis markers • Patient reported outcomes	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results